Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Battelle and Canopy Growth join forces in cannabis research

Battelle, a nonprofit research and development organization, and Canopy Growth, announced the completion of multiple fully legal cannabis imports from Canada to the United States. Battelle and Canopy Growth will work together to advance knowledge surrounding cannabis in support of medical research and novel product development.

Canopy Growth and Battelle completed the rigorous federal approval process required to import cannabis products into the United States and since October 9th, the organizations have completed four product transfers to Battelle’s secure research facilities pursuant to United States Drug Enforcement Agency approvals. For decades, Battelle scientists have been developing methods for testing a variety of controlled substances as well as employing analytical chemistry services for government and private industry.

Notably, product transfers have consisted of a variety of cannabis form factors, including dried cannabis and Canopy Growth’s precisely dosed Softgel capsules.

“As more states, including Ohio, approve the use of medical cannabis to help individuals with certain illnesses, we believe that Battelle will be able to apply our rigorous and independent research and analysis to advance knowledge and improve safety in what is essentially uncharted territory,” said Battelle President and CEO Lou Von Thaer. “We’re pleased to work with Canopy Growth, a respected global leader in this emerging market.”

“We’re pleased to begin collaborating with a trusted institution of Battelle’s reputation,” said Mark Zekulin, President and Co-CEO of Canopy Growth. “This offers us a unique ability to advance standardization, intellectual property development and clinical research that can improve the understanding and legal application of cannabis and cannabinoids around the globe.”

With a DEA Schedule I Researcher License and product obtained from the National Institute on Drug Abuse drug supply program, that is fully legal at the local, state and federal level, Battelle is already conducting research and development studies involving human subjects and smoking behavior at an East Coast research center.

For more information:
Canopy Growth
1 Hershey Dr.
Smiths Falls, Ontario
K7A 0A8
1 855 558 9333 x 122
invest@canopygrowth.com
www.canopygrowth.com

Publication date: